Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18587175 | ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 1 | No | No |
| 18443875 | HYDROCORTISONE ORAL LIQUID FORMULATIONS | February 2024 | December 2024 | Abandon | 10 | 0 | 1 | No | No |
| 18493090 | QUATERNARY AMMONIUM CYCLODEXTRIN AND PREPARATION METHOD AND USES THEREOF, AND SILVER NANOPARTICLE-CYCLODEXTRIN COMPLEX AND PREPARATION METHOD AND USES THEREOF | October 2023 | December 2024 | Allow | 14 | 2 | 1 | No | No |
| 18556634 | PURIFIED PSYCHOACTIVE ALKALOID EXTRACTION USING ACIDIFIED ACETONE | October 2023 | May 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18481549 | FORMULATIONS OF DAZUCORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR | October 2023 | March 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18239072 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | August 2023 | October 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18340702 | COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONS | June 2023 | January 2025 | Abandon | 19 | 3 | 1 | Yes | Yes |
| 18310575 | SOLUTIONS FOR ORAL DOSAGE | May 2023 | January 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18026765 | SPECIALIZED PRO-RESOLVING MEDIATORS (SPMs) AS MELANOCYTE GROWTH PROMOTER AND PRO-SURVIVAL FACTORS AND USES THEREOF | March 2023 | September 2024 | Allow | 18 | 2 | 1 | No | No |
| 18184135 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | March 2023 | December 2024 | Abandon | 21 | 4 | 1 | Yes | No |
| 18115690 | CRILA� AND EGCG COMPOSITIONS FOR TREATMENT OF FIBROIDS | February 2023 | June 2025 | Allow | 27 | 4 | 1 | Yes | No |
| 18075720 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17939569 | COSMETIC COMPOSITION FOR PEEL-OFF-TYPE PACKS, AND METHOD FOR PRODUCING SAME | September 2022 | March 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17903026 | USE OF EFFECTIVE PART EXTRACT OF MONOCHASMA SAVATIERI IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY DISEASE OR TUMOR | September 2022 | November 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17895809 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | August 2022 | May 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17894265 | PHOTOSENSITISING COMPOSITION AND USES THEREOF | August 2022 | November 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17892782 | PHOSPHOLIPID COMPOSITIONS | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17889304 | Milrinone Composition and Method for Administering Same | August 2022 | February 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17843031 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | June 2022 | December 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17589012 | METHODS OF TREATING SARIN EXPOSURE WITH TETRAHYDROCANNABINOL AND CANNABIDIOL COMBINATIONS | January 2022 | May 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17618152 | USING PARASYMPATHOMIMETIC DRUGS ALONE OR, IN COMBINATION WITH ONE OR MORE ALPHA AGONISTS IN PSEUDOPHAKIC PATIENTS, TO CREATE MULTI-FOCALITY | December 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17540563 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | December 2021 | April 2025 | Allow | 40 | 2 | 2 | Yes | No |
| 17602424 | METHODS AND COMPOSITIONS FOR USE IN TREATMENT OF CANCER WITHOUT PSYCHOACTIVE EFFECTS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17594292 | METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATION | October 2021 | February 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17439136 | Macromolecule-Supported TLR Agonists | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17467795 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | Yes | No |
| 17463258 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | August 2021 | March 2025 | Allow | 43 | 3 | 1 | No | No |
| 17310432 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17426411 | ABRASION-RESISTANT OPIOID FORMULATIONS WHICH RESIST ABUSE AND INCLUDE A SEQUESTERED OPIOID ANTAGONIST | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17426281 | DISULPHIDE COMPOUNDS | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17371585 | PHARMACEUTICAL USE | July 2021 | October 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17255887 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF LIVER DISEASES | December 2020 | November 2024 | Allow | 47 | 2 | 0 | No | No |
| 17120800 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | December 2020 | April 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17072726 | USE OF ARTEMISININ FOR TREATING TUMORS INDUCED BY ONCOGENIC VIRUSES AND FOR TREATING VIRAL INFECTIONS | October 2020 | July 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17047155 | NECROPTOSIS INDUCERS OR AUTOPHAGY INHIBITORS OR A COMBINATION THEREOF | October 2020 | March 2025 | Allow | 53 | 2 | 1 | No | No |
| 16932111 | DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERS | July 2020 | December 2022 | Abandon | 29 | 5 | 1 | Yes | Yes |
| 16955221 | SILICONE RESIN-COVERED SILICONE ELASTOMER PARTICLES, ORGANIC RESIN ADDITIVE, AND OTHER USES | June 2020 | September 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16893903 | PHARMACEUTICAL FORMULATION FOR THE ELIMINATION OF CAUSATIVE AGENTS OF HERPESVIRAL INFECTIONS FROM THE TISSUES OF A MACROORGANISM | June 2020 | November 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16879075 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | May 2020 | December 2024 | Allow | 55 | 7 | 1 | Yes | No |
| 15931270 | COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES | May 2020 | March 2025 | Allow | 58 | 2 | 2 | Yes | No |
| 16761779 | EXTENDED RELEASE FORMULATIONS FOR INTRA-ARTICULAR APPLICATIONS | May 2020 | April 2025 | Allow | 60 | 5 | 1 | No | No |
| 16649268 | Ophthalmic Pharmaceutical Composition, Ophthalmic Kit, and Pharmaceutical Application Thereof | March 2020 | August 2024 | Allow | 53 | 5 | 1 | Yes | No |
| 16645975 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | March 2020 | October 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16624439 | Method of Treatment of Cancer | December 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16618779 | LOW-ALCOHOL ANTIMICROBIAL COMPOSITION AND USE THEREOF | December 2019 | January 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16451999 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS | June 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16425580 | ANTIMICROBIAL COMPOSITIONS | May 2019 | July 2024 | Allow | 60 | 2 | 0 | Yes | Yes |
| 16224433 | INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLODEXTRIN A HYDROPHOBIC DRUG, A CO-SOLVENT, AND A PRESERVATIVE | December 2018 | April 2025 | Allow | 60 | 4 | 1 | No | Yes |
| 16210714 | Extruded Immediate Release Abuse Deterrent Pill | December 2018 | March 2020 | Allow | 15 | 1 | 1 | Yes | No |
| 16081290 | GLYCOALKALOID COMBINATIONS AND VARIOUS USES THEREOF | August 2018 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 15780320 | A METHOD FOR PREPARATION OF REDUCIBLE DEGRADABLE HYPERBRANCHED POLYMERIC MICELLES | May 2018 | January 2020 | Allow | 19 | 1 | 0 | No | No |
| 15960004 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF | April 2018 | November 2021 | Abandon | 42 | 2 | 1 | Yes | Yes |
| 15538828 | NANOPARTICLES AND THEIR USE IN CANCER THERAPY | June 2017 | March 2020 | Allow | 32 | 3 | 2 | Yes | No |
| 15332805 | Cyclic Peptidomimetic Compounds as Immunomodulators | October 2016 | February 2018 | Allow | 16 | 0 | 1 | Yes | No |
| 15228674 | 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | August 2016 | July 2019 | Allow | 35 | 2 | 1 | No | No |
| 15115479 | OIL-IN -WATER EMULSION SUNSCREEN COMPOSITION | July 2016 | October 2024 | Allow | 60 | 10 | 0 | No | Yes |
| 14457714 | EXTRUDED IMMEDIATE RELEASE ABUSE DETERRENT PILL | August 2014 | November 2018 | Allow | 51 | 10 | 1 | Yes | Yes |
| 14294764 | CORTICOSTEROID COMPOSITIONS | June 2014 | June 2018 | Allow | 48 | 5 | 1 | Yes | Yes |
| 13642338 | 7-(LH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS | October 2012 | September 2013 | Allow | 11 | 0 | 0 | Yes | No |
| 13245208 | A METHOD OF TREATING ASTHMA | September 2011 | January 2013 | Allow | 16 | 2 | 0 | No | No |
| 13135868 | Small molecules with antimalarial activity | July 2011 | November 2013 | Allow | 28 | 0 | 1 | No | No |
| 12921947 | NOVEL SUBSTANCES ANALOGOUS TO MK8383 AND AGRICULTURAL AND HORTICULTURAL DISEASE CONTROL AGENTS | September 2010 | August 2012 | Allow | 23 | 0 | 0 | Yes | No |
| 12674789 | COMPOSITIONS CONTAINING A SYNERGIC MIXTURE OF POLYOLS AND XYLOGLUCANES AS PHYTOSANITARY AND BIO-FERTILISING PRODUCTS | March 2010 | February 2013 | Allow | 36 | 2 | 1 | Yes | No |
| 12441891 | 3-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | March 2009 | May 2012 | Allow | 38 | 2 | 1 | Yes | No |
| 12034434 | PHARMACEUTICAL COMPOSITION COMPRISING A-LIPOIC ACID FOR INFLAMMATORY DISEASES | February 2008 | October 2009 | Abandon | 19 | 1 | 1 | No | No |
| 11931951 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF A VITAMIN D COMPOUND | October 2007 | September 2009 | Abandon | 22 | 0 | 1 | No | No |
| 10590077 | Of at Use of an Antagonist Compound of at Least One Receptor Selected From a Group Comprising Beta-Adrenergic Receptors, A at1, 5-Ht5 and Galanin Receptor for Preparing a Pharmaceutical Composition for Treating Rosacea | July 2007 | October 2008 | Abandon | 26 | 0 | 1 | No | No |
| 11774892 | STABLE GABAPENTIN COMPOSITIONS | July 2007 | October 2008 | Abandon | 15 | 0 | 1 | No | No |
| 11765872 | SCAR TREATMENT USING PROTEIN PHOSPHATASE INHIBITORS | June 2007 | March 2009 | Abandon | 21 | 1 | 1 | No | No |
| 11764904 | LYOPHILIZED PHARMACEUTICAL COMPOSITION OF PAPAVERINE PHENTOLAMINE AND ALPROSTADIL | June 2007 | August 2009 | Abandon | 26 | 2 | 1 | No | No |
| 11803232 | Topical compositions containing metronidazole | June 2007 | September 2009 | Abandon | 28 | 2 | 1 | No | No |
| 10578015 | Plant-Origin Alpha3-Adrenoceptor Agonist and Use of the Same | May 2007 | October 2008 | Abandon | 30 | 0 | 1 | No | No |
| 11803226 | Topical compositions containing metronidazole | May 2007 | May 2009 | Abandon | 24 | 1 | 1 | No | No |
| 11803269 | Topical compositions containing metronidazole | May 2007 | September 2009 | Abandon | 28 | 2 | 1 | No | No |
| 11803227 | Topical compositions containing metronidazole | May 2007 | September 2009 | Abandon | 28 | 2 | 1 | Yes | No |
| 11747571 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF AGENTS THAT INDUCE BIOLOGIC RESPONSES | May 2007 | September 2009 | Abandon | 28 | 1 | 1 | No | No |
| 11787535 | PHARMACEUTICAL COMPOSITIONS THAT MODULATE HPTPBETA ACTIVITY | April 2007 | August 2009 | Allow | 28 | 2 | 0 | Yes | No |
| 11733591 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | April 2007 | July 2009 | Abandon | 27 | 2 | 1 | No | No |
| 11694935 | TRICYCLIC, HETEROAROMATIC COMPOUNDS MODULATING CXCR4 AND/ OR CXCR7 | March 2007 | July 2009 | Allow | 28 | 1 | 1 | Yes | No |
| 10592994 | Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome | March 2007 | June 2009 | Abandon | 33 | 1 | 1 | No | No |
| 11575741 | Lyophilisate Comprising N-Diaminomethylene-2-Methyl-4,5-Di(Methylsulfonyl)Benzamide | March 2007 | September 2008 | Abandon | 18 | 0 | 1 | No | No |
| 11726176 | Anti-aging composition containing phloretin | March 2007 | August 2009 | Abandon | 28 | 2 | 1 | Yes | No |
| 11597679 | Use of Ppar Agonists to Treat Ruminants | March 2007 | August 2009 | Abandon | 33 | 1 | 1 | No | No |
| 10559868 | Oxazolidinone Antibiotics and Derivatives and Thereof | March 2007 | June 2009 | Abandon | 42 | 0 | 1 | No | No |
| 11681654 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | March 2007 | July 2009 | Abandon | 29 | 2 | 1 | No | No |
| 11570484 | Use of Acetyl L-Carnitine for the Preparation of a Medicine for the Treatment of Neuropathic Pain in Diabetic Patients | March 2007 | July 2009 | Abandon | 31 | 0 | 1 | No | No |
| 11573740 | A COMPOSITION CONTAINING A THIOUREA DERIVATIVE FOR PREVENTING OR TREATING PRURITIC OR IRRITANT SKIN DISEASES | February 2007 | November 2008 | Abandon | 21 | 1 | 1 | No | No |
| 11659876 | Treatments for Congestive Heart Failure | February 2007 | March 2009 | Abandon | 25 | 1 | 1 | No | No |
| 11704665 | Combination therapy for treating or managing acute myelocytic leukemia | February 2007 | May 2009 | Abandon | 27 | 1 | 1 | No | No |
| 11632801 | Use Of Sphingolipids For Prevention And Treatment Of Atherosclerosis | January 2007 | October 2008 | Abandon | 21 | 0 | 1 | No | No |
| 11572186 | Formulation for Stimulating Hair Growth | January 2007 | May 2009 | Abandon | 28 | 1 | 1 | No | No |
| 11587245 | Use of C-Kit Inhibitors for Treating Fibrosis | January 2007 | September 2008 | Abandon | 23 | 1 | 1 | No | No |
| 11603946 | PYRROLO [3,4-H] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | November 2006 | December 2009 | Allow | 37 | 2 | 1 | Yes | Yes |
| 11598746 | Nicardipine injection composition | November 2006 | March 2009 | Abandon | 28 | 2 | 0 | No | No |
| 11590679 | Use of pyridoxamine to treat and/or prevent disease processes | October 2006 | September 2008 | Abandon | 22 | 0 | 1 | No | No |
| 10594081 | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | September 2006 | July 2008 | Abandon | 21 | 1 | 1 | No | No |
| 11515052 | Novel pharmaceutical compositions and methods for treating tumors, including drug-resistant tumors | September 2006 | January 2009 | Abandon | 28 | 1 | 1 | No | No |
| 11496255 | COMPOSITIONS AND METHODS OF REDUCING TISSUE LEVELS OF DRUGS WHEN GIVEN AS OROTATE DERIVATIVES | July 2006 | September 2008 | Allow | 26 | 2 | 1 | Yes | No |
| 10566132 | Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator | July 2006 | July 2008 | Abandon | 29 | 0 | 1 | No | No |
| 11441877 | Prevention of ovarian cancer by administration of a vitamin D compound | May 2006 | June 2009 | Abandon | 36 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner THOMAS, TIMOTHY P.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner THOMAS, TIMOTHY P works in Art Unit 1614 and has examined 131 patent applications in our dataset. With an allowance rate of 31.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner THOMAS, TIMOTHY P's allowance rate of 31.3% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by THOMAS, TIMOTHY P receive 1.73 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by THOMAS, TIMOTHY P is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +55.7% benefit to allowance rate for applications examined by THOMAS, TIMOTHY P. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.8% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 19.4% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 64.3% of appeals filed. This is in the 39% percentile among all examiners. Of these withdrawals, 44.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 56.7% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.8% of allowed cases (in the 86% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.9% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.